Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

An­gi­tia Bio­phar­ma­ceu­ti­cals, a Cal­i­for­nia and Chi­na biotech de­vel­op­ing mus­cu­loskele­tal bi­o­log­ics, has closed a $120 mil­lion Se­ries C led by Bain Cap­i­tal Life Sci­ences, the drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER